DRTS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Alpha Tau Medical Ltd (DRTS) is not a strong buy for a beginner investor with a long-term focus and $50,000-$100,000 to invest. While the stock has shown some positive momentum in the short term, its overbought RSI, lack of significant revenue, and uncertain path to commercialization make it a risky investment at this stage. Holding or exploring other opportunities may be more prudent.
The stock is showing bullish momentum with MACD above 0 and positively expanding, and moving averages in a bullish alignment (SMA_5 > SMA_20 > SMA_200). However, RSI at 82.152 indicates the stock is overbought, suggesting potential for a pullback. Key resistance levels are at 8.037 and 8.4, with support at 6.86 and 6.497.
Japan's approval of Alpha DaRT for head and neck cancer, which validates the platform and de-risks U.S. clinical development.
Analysts have raised price targets, with Citi and H.C. Wainwright seeing upside potential.
Piper Sandler downgraded the stock to Neutral, citing valuation concerns and the lack of near-term revenue realization.
The company's path to full commercialization is still 2-3 years away.
Stock trend analysis suggests a high probability of short-term declines (-2.86% next day, -2.39% next week, -8.38% next month).
In Q4 2025, the company reported no revenue growth (0% YoY) and a net loss of $12.14M, though net income improved by 28.07% YoY. EPS remained negative at -0.14. The company is not yet generating revenue, which is a significant concern for long-term investors.
Analysts are mixed. Citi and H.C. Wainwright have Buy ratings with price targets of $9 and $12, respectively, citing the potential of the radiopharma platform and Japan approval as positives. Piper Sandler downgraded the stock to Neutral with a $5 price target, citing valuation concerns and the lack of near-term revenue.
